Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Simcere Acquires Commercialization Rights to Mabpharm’s Colorectal Cancer Therapy

publication date: Aug 24, 2023

Jiangsu Simcere Zaiming Pharma, a subsidiary of Simcere Group, acquired China commercialization rights to an EGFR inhibitor developed by Taizhou Mabtech Pharma, a Mabpharm company. CMAB009 is a recombinant EGFR chimeric monoclonal antibody, currently under NDA review in China as a first-line treatment for metastatic colorectal cancer in combination with FOLFIRI. Mabpharm said the clinical trial results showed a significant therapeutic effect compared with existing anti-EGFR drugs. Simcere is actively acquiring commercialization rights for assets developed by other China companies. It owns rights to Lynk’s JAK1 inhibitor, a proposed therapy for ankylosing spondylitis, also in the news today. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital